东篱科研大数据发现系统（DRDS）

位置：成果数据库 > 期刊 > 期刊详情页

盐酸厄洛替尼联合放射治疗对食管癌放射敏感性的影响

ISSN号：1005-8664
期刊名称：《中国肿瘤临床与康复》
时间：0
分类：R735.1[医药卫生—肿瘤;医药卫生—临床医学]
作者机构：陕西省宝鸡市中心医院放射治疗科,宝鸡721008
相关基金：陕西省自然基金研究计划（2016JM8110）; 宝鸡市卫生局项目（201308）

作者：朱勇, 王妮娜, 张云, 李晓花, 苏云涛, 杨哲, 胡志纲, 任建, 张红, 何涛

关键词：厄洛替尼, 放射治疗, 食管肿瘤, 放射敏感性, Erlotinib, Radiotherapy, Esophageal neoplasms, Radiosensitivity

中文摘要：

目的探讨厄洛替尼联合放射治疗对食管癌放射敏感性的影响。方法选取2012年1月至2016年10月间陕西省宝鸡市中心医院收治的85例食管癌患者为研究对象。其中,43例接受厄洛替尼联合放射治疗的患者纳入观察组,42例接受单纯放射治疗的患者纳入对照组。比较两组患者放射治疗结束1个月后的疗效和治疗前后的环氧和酶-2（COX-2）和血管内皮生长因子（VEGF）阳性表达的情况。结果放射治疗结束1个月后,观察组患者的治疗有效率为76.7%,高于对照组患者的47.6%,差异有统计学意义（P〈0.05）。治疗前COX-2和VEGF阳性细胞百分率与治疗一个月后病灶最长径总和占出诊时的比例呈正相关,差异均有统计学意义（r=0.849,P=0.02;r=0.811,P=0.03）。治疗前,两组患者的COX-2和VEGF阳性细胞百分率比较,差异无统计学意义（P〉0.05）。放射治疗结束1个月后,两组患者的COX-2和VEGF阳性细胞百分率均低于治疗前,差异有统计学意义（P〈0.05）。放射治疗结束1个月后,观察组患者的COX-2和VEGF阳性细胞百分率低于对照组患者,差异有统计学意义（P〈0.05）。结论厄洛替尼联合放射治疗能够提高治疗食管癌的疗效并能增强患者的放射敏感性。

英文摘要：

Objective To discuss the effect of erlotinib combined with radiotherapy on radiosensitivity in esophageal cancer.Methods Eighty-five patients with esophageal cancer treated at Baoji Central Hospital from January 2012 to October 2016 were selected as the research subjects.Forty-three patients who received erlotinib combined with radiotherapy were included in the observation group and 42 patients who received radiotherapy were included in the control group.At 1 month after the radiotherapy,therapeutic efficacy and positive expression of cyclooxygenase-2（COX-2） and vascular endothelial growth factor（VEGF）before and after treatment were compared.Results At 1 month after therapy,the efficiency rate was76.7% for the observation group which was higher than 47.6% of the control group（P0.05）.Before the treatment,the positive rate of COX-2 and VEGF was positively related to proportion of overall longest diameter one month after therapy compared with the initial visits（r=0.849,P=0.02;r=0.811,P=0.03）.Before treatment,there was no significant difference in percentage of cells test positive for COX-2 and VEGF between the two groups（P0.05）.At 1 month after therapy,percentage of cells test positive for COX-2 and VEGF was lower than before treatment（P0.05）.At 1 month after therapy,percentage of positive cells was lower in the observation group than in the control group（P0.05）.Conclusion Erlotinib combined with radiotherapy can improve the treatment efficacy and enhance the radiosensitivity in patients with esophageal cancer.However,further study is needed to explore its mechanism.

同期刊论文项目